Pharming (Nasdaq: PHAR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2026.
(Neutral)How Sentiment works
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Pharming (Nasdaq: PHAR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2026.
The session starts at 9:30 a.m. GMT and features interim co-CEOs Leverne Marsh and Kenneth Lynard, alongside investor relations executive Michael Levitan. A live webcast and replay will be available on Pharming’s website.
Loading…
Loading translation…
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Leiden, the Netherlands, November 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in London, United Kingdom, on November 16-19, 2026.
Leverne Marsh, Interim Co-CEO & Chief Commercial Officer, and Kenneth Lynard, Interim Co-CEO & Chief Financial Officer, and Michael Levitan, VP Investor Relations and Capital Markets, will participate in a fireside chat Q&A session on Wednesday, November 18 at 9:30 a.m. GMT (10:30 a.m. CET / 4:30 a.m. EST). A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
For more information about this conference, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies representative.
About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.
We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com
Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com
Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: JDeutsch@lyraadvisory.com
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27
